www.idosr.org
©IDOSR PUBLICATIONS

ISSN: 2550-794X

International Digital Organization for Scientific Research
IDOSR JOURNAL OF SCIENTIFIC RESEARCH 10(2):90-95, 2025.
https://doi.org/10.59298/IDOSRJSR/2024/10.2.9095

IDOSRJSR10.200000

Nanoformulations of Natural Compounds in the Treatment of Obesity

Taliikwa Nicholas Ceaser

Department of Pharmacognosy Kampala International University Uganda
Email:ceaser.taliikwa@studwc.kiu.ac.ug

ABSTRACT

Natural compounds such as polyphenols, flavonoids, alkaloids, terpenoids, and saponins demonstrate significant anti-obesity potential by regulating adipogenesis, lipolysis, appetite, and energy expenditure. However, their clinical application is limited by poor solubility, low bioavailability, rapid metabolism, and instability in the gastrointestinal tract. Nanoformulation strategies including polymeric nanoparticles, lipid-based carriers, micelles, dendrimers, and nanoemulsions offer promising solutions to these barriers. By improving solubility, protecting bioactives from degradation, enhancing absorption, and enabling targeted or sustained release, nanoformulations significantly enhance therapeutic efficacy. This review explores the principles of nanoformulation, preclinical and clinical advances, translational barriers, clinical perspectives, and future directions for integrating nanotechnology with natural product–based obesity therapy. Nanoformulations may transform natural bioactives into clinically viable anti-obesity treatments, though long-term safety, cost, and regulatory concerns remain critical challenges.

Keywords: Nanoformulations, Natural compounds, Obesity, Nanocarriers, Bioavailability

INTRODUCTION

Obesity is a complex and multifactorial condition characterized by excessive accumulation of adipose tissue, chronic low-grade inflammation, and metabolic dysregulation[1, 2]. Its rising global prevalence represents one of the most urgent public health challenges, contributing significantly to morbidity and mortality. Obesity is strongly associated with type 2 diabetes mellitus, cardiovascular disease, non-alcoholic fatty liver disease, hypertension, and certain cancers [3, 4]. Conventional management strategies dietary modification, physical activity, pharmacotherapy, and bariatric surgery have shown limited long-term success. Pharmacological therapies often provide modest weight loss, carry safety risks, and rarely address the underlying metabolic dysfunctions[2, 5–7]. This gap has fueled growing interest in natural compounds with anti-obesity potential.

Natural bioactive compounds derived from plants, fruits, vegetables, herbs, and marine sources exert a wide range of biological activities relevant to obesity management[8–11]. Polyphenols such as resveratrol, catechins, and curcumin regulate adipocyte differentiation, oxidative stress, and inflammation[12–15]. Flavonoids like quercetin and rutin demonstrate anti-adipogenic and insulin-sensitizing effects. Alkaloids such as capsaicin and caffeine stimulate thermogenesis and lipolysis. Terpenoids, carotenoids, and saponins modulate lipid metabolism, gut microbiota composition, and appetite control[16–19]. These compounds act through diverse molecular mechanisms, including activation of AMP-activated protein kinase (AMPK), modulation of peroxisome proliferator-activated receptors (PPARs), enhancement of mitochondrial function, and regulation of gut hormone secretion.

Despite compelling preclinical evidence, clinical translation of natural compounds has been hindered by several limitations. Many bioactives exhibit poor aqueous solubility, instability in gastrointestinal conditions, rapid metabolism, and low systemic bioavailability[20]. As a result, oral administration often leads to insufficient therapeutic concentrations at target tissues. For instance, curcumin and resveratrol show potent anti-obesity effects in vitro and in animal models, but their clinical efficacy is severely compromised by poor absorption and rapid clearance[20]. This gap between laboratory efficacy and clinical outcomes underscores the urgent need for novel delivery systems.

Nanotechnology offers promising solutions. By encapsulating natural compounds within nanocarriers, it is possible to overcome solubility and stability barriers, protect compounds from enzymatic degradation, prolong circulation time, and improve bioavailability. Nanoformulations can also enable site-specific targeting, reducing systemic side effects and enhancing therapeutic outcomes[21–23]. Lipid-based carriers such as liposomes, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs) have been widely used for natural product delivery. Polymeric nanoparticles, dendrimers, and nanoemulsions provide additional versatility, allowing sustained release and functionalization with targeting ligands[21, 24–27].

The benefits of nanoformulation extend beyond pharmacokinetics. Encapsulation often enhances the biological activity of natural compounds by increasing their cellular uptake, facilitating interaction with molecular targets, and allowing combination delivery of multiple agents for synergistic effects[28–31]. For example, nanoencapsulated curcumin not only demonstrates higher bioavailability but also produces greater suppression of adipogenesis and inflammation in obese models compared to free curcumin[32–35]. Similarly, nanoemulsified green tea catechins exhibit improved stability and stronger appetite-suppressing effects. This review explores the role of nanoformulations of natural compounds in the treatment of obesity. Section 2 outlines the principles and design of nanoformulations for natural bioactives. Section 3 summarizes advances in preclinical and clinical research. Section 4 examines translational barriers. Section 5 highlights clinical perspectives and potential integration into obesity care. Section 6 discusses future directions and opportunities for innovation.

2. Principles of Nanoformulations for Natural Compounds

Nanoformulations are engineered nanoscale delivery systems designed to encapsulate natural compounds and enhance their pharmacological performance. The most common strategies include lipid-based carriers, polymeric nanoparticles, dendrimers, micelles, and nanoemulsions. Each approach addresses specific limitations of natural bioactives.

Lipid-based nanocarriers such as liposomes, SLNs, and NLCs provide biocompatible matrices capable of encapsulating both hydrophilic and lipophilic natural compounds. They improve solubility, protect bioactives from hydrolysis and enzymatic degradation, and enable controlled release[24, 25, 36].

Polymeric nanoparticles, often made from PLGA, chitosan, or polylactic acid, allow sustained release and enhanced stability. Chitosan-based nanoparticles, for example, are mucoadhesive and improve intestinal absorption of polyphenols[37–40].

Dendrimers offer high loading capacity and multivalent surface functionalization. Their tunable architecture makes them ideal for co-delivery of natural compounds with synergistic agents[41–43].

Micelles and nanoemulsions improve solubilization of poorly water-soluble phytochemicals such as carotenoids or curcumin. Nanoemulsions are particularly useful for oral delivery, where they spontaneously form stable dispersions in gastrointestinal fluids[44].

Functionalization with ligands such as peptides, polysaccharides, or antibodies enables active targeting of adipose tissue, liver, or intestinal receptors. Stimuli-responsive systems release bioactives in response to pH, enzymatic activity, or redox conditions, ensuring delivery at sites of action.

Together, these principles illustrate how nanoformulations transform poorly bioavailable natural compounds into viable therapeutic candidates for obesity.

3. Advances in Preclinical and Clinical Studies

Preclinical studies have consistently demonstrated that nanoformulations significantly enhance the efficacy of natural compounds in obesity models. Curcumin-loaded nanoparticles show improved anti-adipogenic activity, greater suppression of inflammatory cytokines, and enhanced activation of AMPK compared to free curcumin. In obese rodents, nano-curcumin reduces body weight, improves glucose tolerance, and decreases hepatic lipid accumulation[45].

Resveratrol nanoformulations enhance stability and absorption, resulting in improved regulation of lipid metabolism and reduced fat accumulation. Studies with polymeric and lipid-based resveratrol nanoparticles demonstrate stronger effects on mitochondrial function and insulin sensitivity than unformulated resveratrol[46–49].

Green tea catechins and **epigallocatechin gallate (EGCG)** delivered through nanoemulsions exhibit superior bioavailability and enhanced effects on thermogenesis and appetite suppression. These formulations increase PYY and GLP-1 secretion, leading to reduced food intake in animal models[50–52].

Capsaicin nanoformulations improve thermogenic activity and lipid oxidation, contributing to enhanced energy expenditure. Similarly, nanoencapsulated quercetin demonstrates amplified effects on adipocyte apoptosis and reduced lipid accumulation[53].

Clinical studies, though limited, are emerging. Nano-curcumin has shown improved bioavailability and metabolic benefits in small-scale human trials. Nanoformulated EGCG supplements exhibit enhanced stability and stronger effects on weight reduction compared to conventional formulations. While larger clinical trials are needed, these early findings support the translational potential of nanoformulated natural compounds[54].

4. Translational Barriers

Despite encouraging evidence, several challenges hinder the translation of natural compound nanoformulations into clinical practice. Stability is a major issue, as lipid nanoparticles and nanoemulsions may undergo phase separation, crystallization, or drug leakage during storage. Developing robust formulations with long shelf life is critical[55].

Manufacturing scalability poses another barrier. Producing nanoformulations with consistent particle size, encapsulation efficiency, and release profiles at industrial scale is technically demanding and costly. Batch variability remains a concern for regulatory approval[56].

Safety concerns must be addressed. While lipids and polymers are generally considered biocompatible, surfactants and stabilizers can cause toxicity or gastrointestinal irritation. Long-term studies evaluating nanoparticle accumulation and potential systemic effects are essential[57].

Regulatory challenges also complicate translation. Natural compound nanoformulations often fall into a gray area between nutraceuticals and pharmaceuticals, creating uncertainty in approval pathways[58, 59]. Demonstrating reproducibility, bioequivalence, and clinical efficacy is required for regulatory acceptance.

Finally, patient variability adds complexity. Responses to natural compounds depend on genetics, gut microbiota, and metabolic status, necessitating personalized approaches. Cost-effectiveness and accessibility also remain important considerations, especially for widespread application in public health [60].

5. Clinical Perspectives

Clinically, nanoformulations of natural compounds offer exciting opportunities to integrate phytotherapy into mainstream obesity management. By transforming poorly bioavailable bioactives into effective formulations, nanotechnology bridges the gap between traditional remedies and evidence-based medicine[28, 31].

Oral delivery is the most patient-friendly route, and nanoformulations have shown success in enhancing absorption of curcumin, resveratrol, and catechins. Incorporation into functional foods, beverages, or dietary supplements could increase accessibility and acceptance. For example, nanoemulsified catechin beverages may provide appetite suppression and metabolic benefits in a convenient format[61].

Combination strategies are particularly promising. Co-encapsulation of synergistic compounds, such as curcumin and piperine, or resveratrol and quercetin, may produce additive effects on weight reduction and metabolic regulation. Lipid nanoparticles and polymeric carriers are well suited for such multi-agent delivery.

However, clinical adoption requires rigorous trials to establish efficacy, safety, and cost-effectiveness. Long-term studies must demonstrate that nanoformulations not only improve pharmacokinetics but also produce sustained weight loss, improved metabolic outcomes, and reduced comorbidities. Patient-centered considerations, including affordability, adherence, and cultural acceptance, will influence real-world impact.

6. Future Directions

Future innovations in nanoformulations of natural compounds will focus on personalized nutrition and medicine. Advances in metabolomics, genomics, and microbiome profiling will enable tailoring of nanoformulated supplements to individual metabolic needs.

Smart and stimuli-responsive systems will become increasingly important, allowing controlled release of bioactives in response to physiological cues such as pH, enzymes, or microbial metabolites. This could optimize efficacy while minimizing side effects.

Hybrid nanoformulations combining natural compounds with conventional drugs may provide synergistic benefits, targeting multiple obesity-related pathways simultaneously. For example, nanoformulations delivering curcumin alongside GLP-1 analogs could enhance satiety and anti-inflammatory effects.

Integration with **functional foods** represents another exciting direction. Nanoencapsulated bioactives could be incorporated into daily diets, offering preventive and therapeutic benefits without requiring pharmaceutical dosing.

Collaboration across disciplines including nanotechnology, nutrition science, clinical medicine, and regulatory policy will be critical. Standardization of production, safety evaluation, and regulatory frameworks must advance in parallel with scientific innovation.

If these challenges are met, nanoformulations of natural compounds could become central to obesity management, combining the safety and accessibility of natural products with the precision and efficacy of nanomedicine.

CONCLUSION

Natural compounds hold immense promise for obesity treatment, but their clinical use has been hampered by poor bioavailability and instability. Nanoformulations—including lipid nanoparticles, polymeric carriers, nanoemulsions, and dendrimers—overcome these limitations by enhancing solubility, stability, and targeted delivery. Preclinical and early clinical evidence demonstrates improved efficacy of nanoformulated curcumin, resveratrol, catechins, and other compounds. While translational challenges in stability, manufacturing, safety, and regulation remain, future innovations in personalized nutrition, hybrid formulations, and functional food integration may unlock the full therapeutic potential of natural compounds in obesity management.

REFERENCES

1. Ahmed, B., Konje, J.C.: The epidemiology of obesity in reproduction. Best Pract. Res. Clin. Obstet. Gynaecol. 89, 102342 (2023). https://doi.org/10.1016/j.bpobgyn.2023.102342
2. Ahmed, S.K., Mohammed, R.A.: Obesity: Prevalence, causes, consequences, management, preventive strategies and future research directions. Metab. Open. 27, 100375 (2025). https://doi.org/10.1016/j.metop.2025.100375

3. Ejemot-Nwadiaro, R.I., Betiang, P.A., Basajja, M., Uti, D.E.: Obesity and Climate Change: A Two-way Street with Global Health Implications. Obes. Med. 100623 (2025). https://doi.org/10.1016/j.obmed.2025.100623
4. Alum, E.U.: Metabolic memory in obesity: Can early-life interventions reverse lifelong risks? Obes. Med. 55, 100610 (2025). https://doi.org/10.1016/j.obmed.2025.100610
5. Uti, D.E., Atangwho, I.J., Omang, W.A., Alum, E.U., Obeten, U.N., Udeozor, P.A., Agada, S.A., Bawa, I., Ogbu, C.O.: Cytokines as key players in obesity low grade inflammation and related complications. Obes. Med. 54, 100585 (2025). https://doi.org/10.1016/j.obmed.2025.100585
6. Uti, D.E., Atangwho, I.J., Alum, E.U., Egba, S.I., Ugwu, O.P.-C., Ikechukwu, G.C.: Natural Antidiabetic Agents: Current Evidence and Development Pathways from Medicinal Plants to Clinical use. Nat. Prod. Commun. 20, 1934578X251323393 (2025). https://doi.org/10.1177/1934578X251323393
7. Izah, S.C., Betiang, P.A., Paul-Chima Ugwu, O., Ainebyoona, C., Uti, D.E., Echegu, D.A., Alum, B.N.: The Ketogenic Diet in Obesity Management: Friend or Foe? Cell Biochem. Biophys. (2025). https://doi.org/10.1007/s12013-025-01878-0
8. Aware, C.B., Patil, D.N., Suryawanshi, S.S., Mali, P.R., Rane, M.R., Gurav, R.G., Jadhav, J.P.: Natural bioactive products as promising therapeutics: A review of natural product-based drug development. South Afr. J. Bot. 151, 512–528 (2022). https://doi.org/10.1016/j.sajb.2022.05.028
9. Monroy-García, I.N., Torres-Romero, S., Castro-Ochoa, L.D., Mendoza-Acosta, A., Viveros-Valdez, E., Ayala-Zavala, F.: Bioactive Compounds from Marine Macroalgae: A Natural Defense Against Oxidative Stress-Related Diseases. Stresses. 5, 22 (2025). https://doi.org/10.3390/stresses5010022
10. Ragozzino, C., Casella, V., Coppola, A., Scarpato, S., Buonocore, C., Consiglio, A., Palma Esposito, F., Galasso, C., Tedesco, P., Della Sala, G., de Pascale, D., Vitale, L., Coppola, D.: Last Decade Insights in Exploiting Marine Microorganisms as Sources of New Bioactive Natural Products. Mar. Drugs. 23, 116 (2025). https://doi.org/10.3390/md23030116
11. Shi, R., Dan, B., Lü, L.: Bioactive effects advances of natural polysaccharides. J. Future Foods. 3, 234–239 (2023). https://doi.org/10.1016/j.jfutfo.2023.02.005
12. Alves-Santos, A.M., Sugizaki, C.S.A., Lima, G.C., Naves, M.M.V.: Prebiotic effect of dietary polyphenols: A systematic review. J. Funct. Foods. 74, 104169 (2020). https://doi.org/10.1016/j.jff.2020.104169
13. Aryaeian, N., Sedehi, S.K., Arablou, T.: Polyphenols and their effects on diabetes management: A review. Med. J. Islam. Repub. Iran. 31, 134 (2017). https://doi.org/10.14196/mjiri.31.134
14. Bešlo, D., Golubić, N., Rastija, V., Agić, D., Karnaš, M., Šubarić, D., Lučić, B.: Antioxidant Activity, Metabolism, and Bioavailability of Polyphenols in the Diet of Animals. Antioxidants. 12, 1141 (2023). https://doi.org/10.3390/antiox12061141
15. Nowak, M., Tryniszewski, W., Sarniak, A., Wlodarczyk, A., Nowak, P.J., Nowak, D.: Concentration Dependence of Anti- and Pro-Oxidant Activity of Polyphenols as Evaluated with a Light-Emitting Fe2+-Egta-H2O2 System. Molecules. 27, 3453 (2022). https://doi.org/10.3390/molecules27113453
16. Silva-Pinto, P.A., de Pontes, J.T.C., Aguilar-Morón, B., Canales, C.S.C., Pavan, F.R., Roque-Borda, C.A.: Phytochemical insights into flavonoids in cancer: Mechanisms, therapeutic potential, and the case of quercetin. Heliyon. 11, e42682 (2025). https://doi.org/10.1016/j.heliyon.2025.e42682
17. Tuli, H.S., Garg, V.K., Bhushan, S., Uttam, V., Sharma, U., Jain, A., Sak, K., Yadav, V., Lorenzo, J.M., Dhama, K., Behl, T., Sethi, G.: Natural flavonoids exhibit potent anticancer activity by targeting microRNAs in cancer: A signature step hinting towards clinical perfection. Transl. Oncol. 27, 101596 (2023). https://doi.org/10.1016/j.tranon.2022.101596
18. Zahra, M., Abrahamse, H., George, B.P.: Flavonoids: Antioxidant Powerhouses and Their Role in Nanomedicine. Antioxidants. 13, 922 (2024). https://doi.org/10.3390/antiox13080922
19. Zhou, M., Ma, J., Kang, M., Tang, W., Xia, S., Yin, J., Yin, Y.: Flavonoids, gut microbiota, and host lipid metabolism. Eng. Life Sci. 24, 2300065 (2023). https://doi.org/10.1002/elsc.202300065
20. Wang, H., Di, W., Gao, X., Guo, Y., Tang, T., Bai, X., Cao, H.: Materials, Syntheses and Biomedical Applications of Nano-Quercetin Formulations: A Comprehensive Literature Review. Int. J. Nanomedicine. 20, 8729–8764 (2025). https://doi.org/10.2147/IJN.S517079
21. Al Tahan, M.A., Al-Khattawi, A., Russell, C.: Oral peptide delivery Systems: Synergistic approaches using polymers, lipids, Nanotechnology, and needle-based carriers. J. Drug Deliv. Sci. Technol. 112, 107205 (2025). https://doi.org/10.1016/j.jddst.2025.107205
22. Awlqadr, F.H., Majeed, K.R., Altemimi, A.B., Hassan, A.M., Qadir, S.A., Saeed, M.N., Faraj, A.M., Salih, T.H., Abd Al-Manhel, A.J., Najm, M.A.A., Tsakali, E., Van Impe, J.F.M., Abd El-Maksoud, A.A., Abedelmaksoud, T.G.: Nanotechnology-based herbal medicine: Preparation, synthesis, and applications in food and medicine. J. Agric. Food Res. 19, 101661 (2025). https://doi.org/10.1016/j.jafr.2025.101661
23. Alum, E.U., Nwuruku, O.A., Ugwu, O.P.-C., Uti, D.E., Alum, B.N., Edwin, N.: Harnessing nature: plant-derived nanocarriers for targeted drug delivery in cancer therapy. Phytomedicine Plus. 5, 100828 (2025). https://doi.org/10.1016/j.phyplu.2025.100828

24. Plaza-Oliver, M., Santander-Ortega, M.J., Lozano, M.Victoria.: Current approaches in lipid-based nanocarriers for oral drug delivery. Drug Deliv. Transl. Res. 11, 471–497 (2021). https://doi.org/10.1007/s13346-021-00908-7
25. Xu, Y., Michalowski, C.B., Koehler, J., Darwish, T., Guccio, N., Alcaino, C., Domingues, I., Zhang, W., Marotti, V., Van Hul, M., Paone, P., Koutsoviti, M., Boyd, B.J., Drucker, D.J., Cani, P.D., Reimann, F., Gribble, F.M., Beloqui, A.: Smart control lipid-based nanocarriers for fine-tuning gut hormone secretion. Sci. Adv. 10, eadq9909 (2024). https://doi.org/10.1126/sciadv.adq9909
26. Yun, Y., An, J., Kim, H.J., Choi, H.K., Cho, H.-Y.: Recent advances in functional lipid-based nanomedicines as drug carriers for organ-specific delivery. Nanoscale. (2025). https://doi.org/10.1039/D4NR04778H
27. Uti, D.E., Omang, W.A., Alum, E.U., Ugwu, O.P.-C., Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Combined Hyaluronic Acid Nanobioconjugates Impair CD44-Signaling for Effective Treatment Against Obesity: A Review of Comparison with Other Actors. Int. J. Nanomedicine. 20, 10101–10126 (2025). https://doi.org/10.2147/IJN.S529250
28. Ashrafizadeh, M., Delfi, M., Zarrabi, A., Bigham, A., Sharifi, E., Rabiee, N., Paiva-Santos, A.C., Kumar, A.P., Tan, S.C., Hushmandi, K., Ren, J., Zare, E.N., Makvandi, P.: Stimuli-responsive liposomal nanoformulations in cancer therapy: Pre-clinical & clinical approaches. J. Controlled Release. 351, 50–80 (2022). https://doi.org/10.1016/j.jconrel.2022.08.001
29. Hwang, D., Ramsey, J.D., Kabanov, A.V.: Polymeric Micelles for the Delivery of Poorly Soluble Drugs: from Nanoformulation to Clinical Approval. Adv. Drug Deliv. Rev. 156, 80–118 (2020). https://doi.org/10.1016/j.addr.2020.09.009
30. Kevadiya, B.D., Woldstad, C., Ottemann, B.M., Dash, P., Sajja, B.R., Lamberty, B., Morsey, B., Kocher, T., Dutta, R., Bade, A.N., Liu, Y., Callen, S.E., Fox, H.S., Byrareddy, S.N., McMillan, J.M., Bronich, T.K., Edagwa, B.J., Boska, M.D., Gendelman, H.E.: Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution. Theranostics. 8, 256–276 (2018). https://doi.org/10.7150/thno.22764
31. Loo, C.-Y., Lee, W.-H., Zhou, Q.T.: Recent Advances in Inhaled Nanoformulations of Vaccines and Therapeutics Targeting Respiratory Viral Infections. Pharm. Res. 40, 1015–1036 (2023). https://doi.org/10.1007/s11095-023-03520-1
32. Ahmed, M.: Targeting aging pathways with natural compounds: a review of curcumin, epigallocatechin gallate, thymoquinone, and resveratrol. Immun. Ageing A. 22, 28 (2025). https://doi.org/10.1186/s12979-025-00522-y
33. Barati, S., Yadegari, A., Shahmohammadi, M., Azami, F., Tahmasebi, F., Rouhani, M.R., Kazemi, S., Asl, E.R.: Curcumin as a promising therapeutic agent for diabetic neuropathy: from molecular mechanisms to functional recovery. Diabetol. Metab. Syndr. 17, 314 (2025). https://doi.org/10.1186/s13098-025-01884-5
34. El-Saadony, M.T., Yang, T., Korma, S.A., Sitohy, M., Abd El-Mageed, T.A., Selim, S., Al Jaouni, S.K., Salem, H.M., Mahmmod, Y., Soliman, S.M., Mo'men, S.A.A., Mosa, W.F.A., El-Wafai, N.A., Abou-Aly, H.E., Sitohy, B., Abd El-Hack, M.E., El-Tarabily, K.A., Saad, A.M.: Impacts of turmeric and its principal bioactive curcumin on human health: Pharmaceutical, medicinal, and food applications: A comprehensive review. Front. Nutr. 9, 1040259 (2023). https://doi.org/10.3389/fnut.2022.1040259
35. Chen, Y., Lu, Y., Lee, R.J., Xiang, G.: Nano Encapsulated Curcumin: And Its Potential for Biomedical Applications. Int. J. Nanomedicine. 15, 3099–3120 (2020). https://doi.org/10.2147/IJN.S210320
36. Kumar, R., Dkhar, D.S., Kumari, R., Divya, Mahapatra, S., Srivastava, A., Dubey, V.K., Chandra, P.: Ligand conjugated lipid-based nanocarriers for cancer theranostics. Biotechnol. Bioeng. 119, 3022–3043 (2022). https://doi.org/10.1002/bit.28205
37. Austria, E., Bilek, M., Varamini, P., Akhavan, B.: Breaking biological barriers: Engineering polymeric nanoparticles for cancer therapy. Nano Today. 60, 102552 (2025). https://doi.org/10.1016/j.nantod.2024.102552
38. Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez, G., Merinero, M., Argüelles-Arias, F., Alcudia, A.: Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects. Nanomaterials. 10, 1403 (2020). https://doi.org/10.3390/nano10071403
39. Herdiana, Y., Wathoni, N., Shamsuddin, S., Muchtaridi, M.: Scale-up polymeric-based nanoparticles drug delivery systems: Development and challenges. OpenNano. 7, 100048 (2022). https://doi.org/10.1016/j.onano.2022.100048
40. kapoor, D. u, Garg, R., Gaur, M., Prajapati, B.G., Agrawal, G., Bhattacharya, S., Elossaily, G.M.: Polymeric nanoparticles approach and identification and characterization of novel biomarkers for colon cancer. Results Chem. 6, 101167 (2023). https://doi.org/10.1016/j.rechem.2023.101167
41. Abedi-Gaballu, F., Dehghan, G., Ghaffari, M., Yekta, R., Abbaspour-Ravasjani, S., Baradaran, B., Dolatabadi, J.E.N., Hamblin, M.R.: PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy. Appl. Mater. Today. 12, 177–190 (2018). https://doi.org/10.1016/j.apmt.2018.05.002
42. Alamos-Musre, S., Beltrán-Chacana, D., Moyano, J., Márquez-Miranda, V., Duarte, Y., Miranda-Rojas, S., Olguín, Y., Fuentes, J.A., González-Nilo, D., Otero, M.C.: From Structure to Function: The Promise of

PAMAM Dendrimers in Biomedical Applications. Pharmaceutics. 17, 927 (2025). https://doi.org/10.3390/pharmaceutics17070927

43. Pérez-Ferreiro, M., M. Abelairas, A., Criado, A., Gómez, I.J., Mosquera, J.: Dendrimers: Exploring Their Wide Structural Variety and Applications. Polymers. 15, 4369 (2023). https://doi.org/10.3390/polym15224369
44. Tomar, R., Das, S.S., Balaga, V.K.R., Tambe, S., Sahoo, J., Rath, S.K., Ruokolainen, J., Kesari, K.K.: Therapeutic Implications of Dietary Polyphenols-Loaded Nanoemulsions in Cancer Therapy. ACS Appl. Bio Mater. 7, 2036–2053 (2024). https://doi.org/10.1021/acsabm.3c01205
45. Yavarpour-Bali, H., Ghasemi-Kasman, M., Pirzadeh, M.: Curcumin-loaded nanoparticles: a novel therapeutic strategy in treatment of central nervous system disorders. Int. J. Nanomedicine. 14, 4449–4460 (2019). https://doi.org/10.2147/IJN.S208332
46. Cavalcante de Freitas, P.G., Rodrigues Arruda, B., Araújo Mendes, M.G., Barroso de Freitas, J.V., da Silva, M.E., Sampaio, T.L., Petrilli, R., Eloy, J.O.: Resveratrol-Loaded Polymeric Nanoparticles: The Effects of D-α-Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS) on Physicochemical and Biological Properties against Breast Cancer In Vitro and In Vivo. Cancers. 15, 2802 (2023). https://doi.org/10.3390/cancers15102802
47. Jalili, C., Kiani, A., Gholami, M., Bahrehmand, F., Fakhri, S., Kakehbaraei, S., Kakebaraei, S.: Brain targeting based nanocarriers loaded with resveratrol in Alzheimer's disease: A review. IET Nanobiotechnol. 17, 154–170 (2023). https://doi.org/10.1049/nbt2.12127
48. Sharifi-Rad, J., Quispe, C., Mukazhanova, Z., Knut, E., Turgumbayeva, A., Kipchakbayeva, A., Seitimova, G., Mahomoodally, M.F., Lobine, D., Koay, A., Wang, J., Sheridan, H., Leyva-Gómez, G., Prado-Audelo, M.L.D., Cortes, H., Rescigno, A., Zucca, P., Sytar, O., Imran, M., Rodrigues, C.F., Cruz-Martins, N., Ekiert, H., Kumar, M., Abdull Razis, A.F., Sunusi, U., Kamal, R.M., Szopa, A.: Resveratrol-Based Nanoformulations as an Emerging Therapeutic Strategy for Cancer. Front. Mol. Biosci. 8, (2021). https://doi.org/10.3389/fmolb.2021.649395
49. Wang, W., Zhou, M., Xu, Y., Peng, W., Zhang, S., Li, R., Zhang, H., Zhang, H., Cheng, S., Wang, Y., Wei, X., Yue, C., Yang, Q., Chen, C.: Resveratrol-Loaded TPGS-Resveratrol-Solid Lipid Nanoparticles for Multidrug-Resistant Therapy of Breast Cancer: In Vivo and In Vitro Study. Front. Bioeng. Biotechnol. 9, 762489 (2021). https://doi.org/10.3389/fbioe.2021.762489
50. Capasso, L., De Masi, L., Sirignano, C., Maresca, V., Basile, A., Nebbioso, A., Rigano, D., Bontempo, P.: Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential. Molecules. 30, 654 (2025). https://doi.org/10.3390/molecules30030654
51. Jiang, P., Xu, C., Chen, L., Chen, A., Wu, X., Zhou, M., Haq, I.U., Mariyam, Z., Feng, Q.: EGCG inhibits CSC-like properties through targeting miR-485/CD44 axis in A549-cisplatin resistant cells. Mol. Carcinog. 57, 1835–1844 (2018). https://doi.org/10.1002/mc.22901
52. Mokra, D., Joskova, M., Mokry, J.: Therapeutic Effects of Green Tea Polyphenol (–)-Epigallocatechin-3-Gallate (EGCG) in Relation to Molecular Pathways Controlling Inflammation, Oxidative Stress, and Apoptosis. Int. J. Mol. Sci. 24, 340 (2022). https://doi.org/10.3390/ijms24010340
53. Maleki, M.H., Abdizadeh Javazm, S., Dastghaib, S., Panji, A., Hojjati Far, M., Mahmoodi, H., Siri, M., Shafiee, S.M.: The effect of quercetin on adipogenesis, lipolysis, and apoptosis in 3T3-L1 adipocytes: The role of SIRT1 pathways. Obes. Sci. Pract. 10, e752 (2024). https://doi.org/10.1002/osp4.752
54. Bertoncini-Silva, C., Vlad, A., Ricciarelli, R., Giacomo Fassini, P., Suen, V.M.M., Zingg, J.-M.: Enhancing the Bioavailability and Bioactivity of Curcumin for Disease Prevention and Treatment. Antioxidants. 13, 331 (2024). https://doi.org/10.3390/antiox13030331
55. Rehman, M., Tahir, N., Sohail, M.F., Qadri, M.U., Duarte, S.O.D., Brandão, P., Esteves, T., Javed, I., Fonte, P.: Lipid-Based Nanoformulations for Drug Delivery: An Ongoing Perspective. Pharmaceutics. 16, 1376 (2024). https://doi.org/10.3390/pharmaceutics16111376
56. Javid-Naderi, M.J., Shaegh, S.A.M.: Advanced microfluidic techniques for the preparation of solid lipid nanoparticles: Innovations and biomedical applications. Int. J. Pharm. X. 100399 (2025). https://doi.org/10.1016/j.ijpx.2025.100399
57. van Wyk, A.S., Prinsloo, G.: Health, safety and quality concerns of plant-based traditional medicines and herbal remedies. South Afr. J. Bot. 133, 54–62 (2020). https://doi.org/10.1016/j.sajb.2020.06.031
58. Havelikar, U., Ghorpade, K.B., Kumar, A., Patel, A., Singh, M., Banjare, N., Gupta, P.N.: Comprehensive insights into mechanism of nanotoxicity, assessment methods and regulatory challenges of nanomedicines. Discov. Nano. 19, 165 (2024). https://doi.org/10.1186/s11671-024-04118-1
59. Musazzi, U.M., Franzè, S., Condorelli, F., Minghetti, P., Caliceti, P.: Feeding Next-Generation Nanomedicines to Europe: Regulatory and Quality Challenges. Adv. Healthc. Mater. 12, 2301956 (2023). https://doi.org/10.1002/adhm.202301956
60. Alum, E.U.: Role of phytochemicals in cardiovascular disease management: Insights into mechanisms, efficacy, and clinical application. Phytomedicine Plus. 5, 100695 (2025). https://doi.org/10.1016/j.phyplu.2024.100695

61. Date, A.A., Hanes, J., Ensign, L.M.: Nanoparticles for oral delivery: design, evaluation and state-of-the-art. J. Control. Release Off. J. Control. Release Soc. 240, 504–526 (2016). https://doi.org/10.1016/j.jconrel.2016.06.016

CITE AS: Taliikwa Nicholas Ceaser (2025). Nanoformulations of Natural Compounds in the Treatment of Obesity. IDOSR JOURNAL OF SCIENTIFIC RESEARCH 10(2):90-95. https://doi.org/10.59298/IDOSRJSR/2024/10.2.9095